Lorenc-Koci Elżbieta, Górny Magdalena, Chwatko Grażyna, Kamińska Kinga, Iciek Małgorzata, Rogóż Zofia
Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
The Chair of Medical Biochemistry, Jagiellonian University Medical College, 7 Kopernika Street, Kraków, 31-034, Poland.
Pharmacol Rep. 2024 Aug;76(4):863-877. doi: 10.1007/s43440-024-00607-3. Epub 2024 Jun 21.
Phencyclidine, an NMDA receptor antagonist, is frequently used to model behavioral and neurochemical changes correlated with schizophrenia in laboratory animals. The present study aimed to examine the effects of repeated administration of phencyclidine during early postnatal development on the contents of glutathione and sulfur-containing amino acids, as well as the activity of antioxidant enzymes in the brain of 12-day-old rats, and schizophrenia-like symptoms in adulthood.
Male Sprague-Dawley pups were administered phencyclidine (10 mg/kg) or saline subcutaneously on the postnatal days p2, p6, p9 and p12. In 12-day-old pups, 4 h after the last dose of phencyclidine, the levels of glutathione, cysteine, methionine, and homocysteine, and the enzymatic activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR) were measured in the frontal cortex, hippocampus, and striatum. In 70-72-day-old rats, schizophrenia-like symptoms were assessed using behavioral tests.
Biochemical data showed that perinatal phencyclidine treatment significantly reduced glutathione and cysteine levels in all brain structures studied, methionine was diminished in the striatum, and homocysteine in both the frontal cortex and striatum. GR activity was increased in the frontal cortex while SODactivity was decreased in the hippocampus. Behaviorally, perinatal phencyclidine induced long-term deficits in social and cognitive function and a decrease in locomotor activity assessed as the time of walking. Finally, perinatal treatment with phencyclidine resulted in a significant reduction in body weight gain over time.
Our research provides further evidence for the usefulness of the phencyclidine-induced neurodevelopmental model of schizophrenia for studying the pathogenesis of schizophrenia.
苯环己哌啶是一种N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,常用于在实验动物中模拟与精神分裂症相关的行为和神经化学变化。本研究旨在探讨在出生后早期发育阶段重复给予苯环己哌啶对12日龄大鼠脑内谷胱甘肽和含硫氨基酸含量、抗氧化酶活性以及成年后精神分裂症样症状的影响。
雄性斯普拉格-道利幼崽在出生后第2、6、9和12天皮下注射苯环己哌啶(10mg/kg)或生理盐水。在12日龄幼崽中,最后一剂苯环己哌啶给药4小时后,测量额叶皮质、海马体和纹状体中谷胱甘肽、半胱氨酸、蛋氨酸和同型半胱氨酸的水平,以及超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GPx)和谷胱甘肽还原酶(GR)的酶活性。在70 - 72日龄大鼠中,使用行为测试评估精神分裂症样症状。
生化数据显示,围产期苯环己哌啶治疗显著降低了所有研究脑区的谷胱甘肽和半胱氨酸水平,纹状体中的蛋氨酸减少,额叶皮质和纹状体中的同型半胱氨酸减少。额叶皮质中的GR活性增加,而海马体中的SOD活性降低。行为学上,围产期苯环己哌啶诱导社交和认知功能的长期缺陷,以及作为行走时间评估的运动活动减少。最后,围产期苯环己哌啶治疗导致体重随时间显著减轻。
我们的研究为苯环己哌啶诱导的精神分裂症神经发育模型在研究精神分裂症发病机制方面的有用性提供了进一步证据。